Connect Biopharma is a developer of novel immune modulators for the treatment of serious autoimmune diseases and inflammation.
Connect Biopharmaceuticals is a clinical-stage company that discovers and develops novel medicines for the treatment of autoimmune diseases and inflammation. They identify and advance our drug candidates through in-house discovery and in-licensing while leveraging qualified CROs for further development. The company successfully completed a phase I clinical trial study on our leading program CBP-307, a novel and selective second-generation S1P1 (a G-protein coupled receptor -GPCR) modulator for the treatment of a range of autoimmune disorders, including multiple sclerosis, inflammatory bowel disease, and psoriasis.Connect Biopharmaceuticals currently conducting two phases 2 clinical studies in patients with ulcerative colitis and Crohn's disease with their lead drug candidate CBP-307. It also concluding a phase 1 study of our second drug candidate CBP-201 in healthy subjects, with a phase 1b study in atopic dermatitis patients expected to commence in Q1, 2019. Connect Biopharmaceuticals was founded in 2012 and is headquartered in Taichang, China.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Aug 24, 2020 | Series C | $115M | 1 | — | — | Detail |
Nov 1, 2016 | Seed | $5M | 2 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Lilly Asia Ventures | — | Series C |
XinYue Equity | — | Seed |
Anlongmed Fund | — | Seed |